Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative
Biomolecules · 28.06.2025 · 15 (7) · 941
DOI: 10.3390/biom15070941 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Biomolecules, online erschienen am 28.06.2025. Verfasst von Bianca Andretto de Mattos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Sorbonne Université, 75013 Paris, France. Hauptthemen laut MEDLINE: Uric Acid, tau Proteins, Purines, Tauopathies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Recherche Alzheimer, Institut Carnot, Capes-Cofecub.
Abstract (Originalsprache)
We aimed to simulate tau abnormalities—specifically hyperphosphorylation and aggregation—that are hallmarks of tauopathies, including Alzheimer’s disease, to evaluate tau-targeting therapies. To model pathological p-tau accumulation at early disease stages, we exposed mouse cortical cultures to redox-active iron from hemin (Hm), a breakdown product of hemoglobin, or challenged them with the excitatory neurotransmitter glutamate. Using the AT8 phospho-specific antibody, we demonstrate that a subtoxic concentration of Hm (3 µM) promotes pathological p-tau accumulation in a subpopulation of cultured cortical neurons and their proximal neurites. Uric acid (UA; 0.1–200 µM), the metabolic end-product of purines in humans, prevented p-tau build-up. Neither xanthine, the immediate precursor of UA, nor allantoin, its oxidized product, reproduced this effect. Live cell imaging studies revealed that UA operates by repressing iron-driven lipid peroxidation. DOT (3 µM), a brain-permeant tetracycline (TC) without antibiotic activity, mimicked UA’s anti-tau and antioxidant effects. Interestingly, both UA and DOT remained effective in preventing p-tau accumulation induced by glutamate (10 µM). To simulate tau aggregation at more advanced disease stages, we conducted a Thioflavin-T aggregation assay. Our findings revealed that UA and DOT prevented tau aggregation seeded by heparin. However, only DOT remained effective when heparin-assembled tau fibrils were used as the seeding material. In summary, our results indicate that UA-elevating agents may hold therapeutic utility for tauopathies. The non-purine compound DOT could serve as an effective alternative to UA-related therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Sorbonne Université, 75013 Paris, France.
- Medical School of Ribeirão Preto, Department of Physiology, University of Sao Paulo, Ribeirão Preto 14040-904, Brazil.
- IMMCA, CONICET-UNT-SIPROSA, Tucumán 4000, Argentina.
- BioCIS, CNRS, Université Paris-Saclay, 91400 Orsay, France.
- Inserm, Membranes et Cibles Thérapeutiques, Service de Santé des Armées, Aix Marseille Université, 13385 Marseille, France.
- Department of Neurology, CIC1424, University Hospital of Guadeloupe, Antilles University, French West Indies, 97159 Pointe-à-Pitre, France.
ORCID-Profile: Bianca Andretto de Mattos, Rodrigo Hernán Tomas-Grau, Thaís Antonia Alves Fernandes, Aurore Tourville, Jean-Michel Brunel, Rosana Chehin, Laurent Ferrié, Bruno Figadère, Patrick Pierre Michel
Förderung
- Fondation Recherche Alzheimer
- Institut Carnot
- Capes-Cofecub
- Capes
- Ministerio de Ciencia, Tecnología e Innovación
- National University of Tucumán
- Program Investissements d'Avenir
- Translational Research Infrastructure for Biotherapies in Neurosciences
Zitieren
APA
Andretto de Mattos, B., Tomas-Grau, R. H., Alves Fernandes, T. A., González-Lizárraga, F., Tourville, A., Ciss, I., Brunel, J. M., Chehin, R., Lannuzel, A., Ferrié, L., Raisman-Vozari, R., Figadère, B., Del Bel, E., & Michel, P. P. (2025). Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative. Biomolecules, 15(7), 941. https://doi.org/10.3390/biom15070941
Vancouver
Andretto de Mattos B, Tomas-Grau RH, Alves Fernandes TA, González-Lizárraga F, Tourville A, Ciss I, et al. Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative. Biomolecules. 2025;15(7):941. doi:10.3390/biom15070941
BibTeX
@article{AndrettodeMattos2025,
author = {Andretto de Mattos, Bianca and Tomas-Grau, Rodrigo Hernán and Alves Fernandes, Thaís Antonia and González-Lizárraga, Florencia and Tourville, Aurore and Ciss, Ismaila and Brunel, Jean-Michel and Chehin, Rosana and Lannuzel, Annie and Ferrié, Laurent and Raisman-Vozari, Rita and Figadère, Bruno and Del Bel, Elaine and Michel, Patrick Pierre},
title = {Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {7},
pages = {941},
doi = {10.3390/biom15070941}
}
EUVIMED